Biosensics

Executive Summary

Biosensics is a digital health and medical device company founded in 2007 by Harvard scientists, specializing in wearable sensors and digital biomarker platforms for neurological and rare disorders. The company provides validated technologies and comprehensive services for clinical trials, remote patient monitoring, and health assessment. By leveraging its proprietary sensors and analytics, Biosensics enables objective, continuous measurement of motor and physiological functions, addressing the need for reliable endpoints in drug development and patient care. With a focus on underserved areas like Parkinson's disease, Huntington's disease, and muscular dystrophies, the company has positioned itself as a key enabler of decentralized clinical trials and real-world evidence generation. Its platform integrates with existing research workflows, offering scalable solutions that reduce site burden and improve data quality. As the demand for digital biomarkers grows, Biosensics is well-placed to capture a share of the expanding digital health market, projected to reach over $500 billion by 2030. The company's deep expertise in sensor technology and its established relationships with academic and pharmaceutical partners provide a solid foundation for future growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation wearable sensor platform for neurological trials70% success
• H1 2027FDA clearance for a novel digital biomarker algorithm for Parkinson's disease60% success
• Q2 2026Strategic partnership with a top-20 pharmaceutical company for remote monitoring in rare disease clinical trials55% success